Goldstein LB, Bonito AJ, Matchar D.
et al. US national survey of physician practices for the secondary and tertiary
prevention of ischemic stroke. Stroke.1995;26:1607-1615.
Lindley RI, Amayo EO, Marshall J.
et al. Acute stroke treatment in UK hospitals: the Stroke Association survey
of consultant opinion. J R Coll Physicians Lond.1995;29:479-484.
Gorelick PB, Sacco RL, Smith DB.
et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary
consensus statement from the National Stroke Association. JAMA.1999;281:1112-1120.
Goldstein LB, Adams R, Becker K.
et al. Primary prevention of ischemic stroke: a statement for healthcare professionals
from the Stroke Council of the American Heart Association. Circulation.2001;103:163-182.
Benson RT, Sacco RL. Stroke prevention: hypertension, diabetes, tobacco, and lipids. Neurol Clin.2000;18:309-319.
Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med.1995;333:1392-1400.
Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Semin Neurol.1998;18:429-440.
Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA.2000;284:2901-2906.
D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication: the
Framingham Study. Stroke.1994;25:40-43.
McAlister FA. Relative treatment effects are consistent across a spectrum of underlying
risks . . usually. Int J Epidemiol.2002;31:76-77.
MacMahon S, Peto R, Cutler J.
et al. Blood pressure, stroke, and coronary heart disease, I: prolonged differences
in blood pressure: prospective observational studies corrected for the regression
dilution bias. Lancet.1990;335:765-774.
Wright JM, Lee C-H, Chambers GK. Systematic review of antihypertensive therapies: does the evidence
assist in choosing a first-line drug? CMAJ.1999;161:25-32.
Psaty BM, Smith NL, Siscovick DS.
et al. Health outcomes associated with antihypertensive therapies used as
first-line agents: a systematic review and meta-analysis. JAMA.1997;277:739-745.
Perry HM, Davis BR, Price TR.
et al. Effect of treating isolated systolic hypertension on the risk of developing
various types and subtypes of stroke. JAMA.2000;284:465-471.
Rodgers A, MacMahon S, Gamble G.
et al. Blood pressure and risk of stroke in patients with cerebrovascular
Staessen JA, Gasowski J, Wang JG.
et al. Risks of untreated and treated isolated systolic hypertension in the
elderly: meta-analysis of outcome trials. Lancet.2000;355:865-872.
Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R.for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis
of randomized controlled trials. Lancet.1999;353:793-796.
Neal B, MacMahon S, Chapman N.for the Blood Pressure Lowering Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering
drugs: results of prospectively designed overviews of randomized trials. Lancet.2000;356:1955-1964.
McAlister FA, Sackett DL. Active-control equivalence trials and antihypertensive agents. Am J Med.2001;111:553-558.
Not Available. Cholesterol, diastolic blood pressure, and stroke: 13000 strokes in
450000 people in 45 prospective cohorts. Lancet.1995;346:1647-1653.
Benfante R, Yano K, Hwang LJ.
et al. Elevated serum cholesterol is a risk factor for both coronary heart
disease and thromboembolic stroke in Hawaiian Japanese men: implications of
shared risk. Stroke.1994;25:814-820.
Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six year mortality from stroke in 350,977
men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med.1989;320:904-910.
Byington RP, Davis BR, Plehn JF.
et al. Reduction in stroke events with pravastatin: Prospective Pravastatin
Pooling (PPP) Project. Circulation.2001;103:387-392.
Plutzky J, Ridker PM. Statins for stroke: the second story? Circulation.2001;103:348-350.
Bucher HC, Griffith LE, Guyatt GH. Effect of HMGCoA reductase inhibitors on stroke: a meta-analysis of
randomized controlled trials. Ann Intern Med.1998;128:89-95.
Warshafsky S, Packard D, Marks SJ.
et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
for prevention of stroke. J Gen Intern Med.1999;14:763-774.
Crouse III JR, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med.1997;157:1305-1310.
White HD, Simes RJ, Anderson NE.
et al. Pravastatin therapy and the risk of stroke. N Engl J Med.2000;343:317-326.
Schwartz GG, Olsson AG, Esekowitz MD.
et al. Effects of atorvastatin on early recurrent ischemic events in acute
coronary syndromes. JAMA.2001;285:1711-1718.
Not Available. Executive summary of the third report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA.2001;285:2486-2497.
Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation:
analysis and implications. Arch Intern Med.1995;155:469-473.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly:
the Framingham Study. Arch Intern Med.1987;147:1561-1564.
Albers GW, Dalen JE, Laupacis A, Manning WJ, Peterson P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest.2001;119(suppl):194S-206S.
Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart
Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial
fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med.1994;154:1449-1457.
Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors
during ASA therapy. J Am Coll Cardiol.2000;35:183-187.
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:
a meta-analysis. Ann Intern Med.1999;131:492-501.
Becker RC, Ansell JJ. Antithrombotic therapy. Arch Intern Med.1995;155:149-161.
Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and
prediction by factors known at the start of outpatient therapy. Am J Med.1989;87:144-152.
Caro JJ, Flegel KM, Orejuela ME, Kelley HE, Speckman JL, Migliaccio-Walle K. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness
in actual practice. CMAJ.1999;161:493-497.
Tanne D, Goldbourt U, Zion M, Reicher-Reiss H, Kaplinsky E, Behar S.for the SPRINT Study Group. Frequency and prognosis of stroke/TIA among 4808 survivors of acute
myocardial infarction. Stroke.1993;24:1490-1495.
Loh E, Sutton MS, Wun CC.
et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med.1997;336:251-257.
Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy
for prevention of death, myocardial infarction and stroke in high risk patients. BMJ.2002;324:71-86.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and
progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med.1993;329:977-986.
The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications
in patients with adult-onset diabetes. Diabetes.1970;19(suppl):789-830.
UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared
with conventional treatment and risk of complications in patients with type
2 diabetes (UKPDS 33). Lancet.1998;352:837-853.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular
and microvascular complications in type 2 diabetes (UKPDS 39). BMJ.1998;317:713-720.
Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ.1989;298:789-794.
Kawachi I, Colditz GA, Stampfer MJ.
et al. Smoking cessation and decreased risk of stroke in women. JAMA.1993;269:232-236.
Law M, Tang JL. An analysis of the effectiveness of interventions intended to help
people stop smoking. Arch Intern Med.1995;155:1933-1941.
Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation [Cochrane
Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001;issue 4.
Rice VH, Stead LF. Nursing interventions for smoking cessation [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001;issue 4.
Ashenden R, Silagy C, Weller D. A systematic review of the effectiveness of promoting lifestyle change
in general practice. Fam Pract.1997;14:160-176.
Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation [Cochrane Review
on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001;issue 4.
Hughes JR, Stead L, Lancaster T. Antidepressants for smoking cessation [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001;issue 4.
Hart RG, Halperin JL, McBride R.
et al. Aspirin for the primary prevention of stroke and other major vascular
events. Arch Neurol.2000;57:326-332.
The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic
Cote R, Battista RN, Abrahamowicz M.
et al. for the Asymptomatic Cervical Bruit Study Group. Lack of effect of ASA in asymptomatic patients with carotid bruits
and substantial carotid narrowing. Ann Intern Med.1995;123:649-655.
de Gaetano G.for the Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a
randomised trial in general practice. Lancet.2001;357:89-95.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on
cardiovascular events in high risk patients. N Engl J Med.2000;342:145-153.
Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures:
a HOPE substudy. Hypertension.2001;38:E28-E32.
Pfeffer MA, Domanski M, Verter J.
et al. The continuation of the Prevention of Events with Angiotensin-Converting
Enzyme Inhibition (PEACE) Trial. Am Heart J.2001;142:375-377.
Fox KM, Henderson JR, Bertrand ME.
et al. The European Trial on reduction of cardiac events with perindopril
in stable coronary artery disease (EUROPA). Eur Heart J.1998;19(suppl J):J52-J55.
Not Available. Major cardiovascular events in hypertensive patients randomized to
doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment
to prevent Heart Attack Trial (ALLHAT). JAMA.2000;283:1967-1975.
McAlister FA, Levine M, Zarnke K.
et al. for the Canadian Hypertension Recommendations Working Group. The 2000 Canadian recommendations for the management of hypertension,
I: therapy. Can J Cardiol.2001;17:543-559.
Benavente O, Moher D, Pham B. Carotid endarterectomy for asymptomatic carotid stenosis: a meta-analysis. BMJ.1998;317:1477-1480.
Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs and effects
on individuals and populations. Lancet.1999;354:1457-1463.
Rodgers A, MacMahon S, Gamble G, Slattery J, Sandercock P, Warlow C. Blood pressure and risk of stroke in patients with cerebrovascular
disease: the United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ.1996;313:147.
Gueyffier F, Boissel JP, Boutitie F.
et al. for the INDANA Project Collaborators. Effect of antihypertensive treatment in patients having already suffered
from stroke: gathering the evidence. Stroke.1997;28:2557-2562.
PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure lowering regimen
among 6105 individuals with previous stroke or transient ischemic attack. Lancet.2001;358:1033-1041.
Strandgaard S. Hypertension and stroke. J Hypertens Suppl.1996;14:S23-S27.
Collins R, Peto R. MRC/BHF Heart Protection Study. Stroke.1999;30:1304.
Not Available. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL)
[Stroke Center Web site]. Available at: http://www.neuro.wustl.edu/stroke/trials.
Accessibility verified July 29, 2002.
European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient
ischaemic attack or minor stroke. Lancet.1993;342:1255-1262.
Diener HC, Lowenthal A. European Stroke Prevention Study 2. J Neurol Sci.1996;143:1-13.
Benavente O, Hart R, Koudstal P, Laupacis A, McBride R. Antiplatelet therapy for preventing stroke in patients with nonvalvular
atrial fibrillation and no previous history of stroke or transient ischemic
attacks. In: Warlow C, Van Gijn J, Sandercock P, eds. Stroke
Module of the Cochrane Database of Systematic Reviews. Oxford, England:
Cochrane Collaboration; 1999.
Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low intensity, fixed-dose warfarin plus
aspirin for high-risk patients with atrial fibrillation: Stroke Prevention
in Atrial Fibrillation III randomised clinical trial. Lancet.1996;348:633-638.
Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA.1999;281:1830-1835.
Johnson ES, Lanes SF, Wentwork III CE, Satterfield MH, Abebe BL, Dicker LW. A metaregression analysis of the dose-response effect of ASA on stroke. Arch Intern Med.1999;159:1248-1253.
Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial:
final results. J Neurol Neurosurg Psychiatry.1991;54:1044-1054.
Hankey GJ, Sudlow CLM, Dunbabin DW. Thienopyridine derivatives versus ASA for preventing stroke and other
serious vascular events in high vascular risk patients [Cochrane Review on
CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001;issue 1.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Secondary Prevention Study 2: dipyridamole and acetylsalicylic
acid in the secondary prevention of stroke. J Neurol Sci.1996;143:1-13.
DeSchryver EL. Design of ESPRIT: an international randomized trial for secondary prevention
after non-disabling cerebral ischemia of arterial origin. Cerebrovasc Dis.2000;10:147-150.
Cina CA, Clase CM, Haynes RB. Carotid endarterectomy for symptomatic carotid stenosis [Cochrane Review
on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2001;issue 1.
Tu JV, Hannan EL, Anderson GM.
et al. The fall and rise of carotid endarterectomy in the United States and
Canada. N Engl J Med.1998;339:1441-1447.
Rothwell PM, Slattery J, Warlow CP. Clinical and angiographic predictors of stroke and death from carotid
endarterectomy: systematic review. BMJ.1997;315:1571-1577.